相关实验视频

Updated: May 17, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

miR-627-5p通过向ANGPTL4来抑制宫癌的恶性进展

Xinghua Wu¹, Kai Lin², Chen Gao²

¹Ningde Clinical Medical College of Fujian Medical University; Ningde Municipal Hospital of Ningde Normal University, Ningde.

European journal of histochemistry : EJH

|April 7, 2025

概括

微RNA-627-5p (miR-627-5p) 通过向ANGPTL4.4来抑制子宫癌 (CC) 的进展. 这项研究揭示了miR-627-5p作为潜在的生物标志物和CC治疗的治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

累积的证据表明miR-627-5p在各种癌症中存在影响.
在宫癌 (CC) 中miR-627-5p的特定作用和机制在很大程度上仍未被描述.
了解miR-627-5p在CC中的功能对于开发向疗法至关重要.

研究的目的:

阐明miR-627-5p抑制CC恶性进展的机制.
在CC中调查miR-627-5p和ANGPTL4之间的调控关系.
评估miR-627-5p作为CC的生物标志物和治疗点的潜在临床影响.

主要方法:

定量实时PCR (qRT-PCR) 用于分析C33A细胞中miR-627-5p和ANGPTL4的mRNA表达.
将miR-627-5p模拟和miR-NC控制转移到C33A细胞中.
功能性检测包括CCK-8,迁移,透漏,流细胞计和西部涂抹,以评估细胞行为.
涉及ANGPTL4过度表达的救援实验.

主要成果:

在C33A细胞中,miR-627-5p的表达下调,而ANGPTL4的表达上调.
miR-627-5p直接准ANGPTL4的3'-UTR,对其表达进行负面调节.
miR-627-5p抑制了扩散,入侵,迁移和上皮细胞-介质细胞过渡 (EMT),同时促进了细胞亡和S相停止.
对ANGPTL4的过度表达逆转了miR-627-5p的抑制作用.

结论:

miR-627-5p通过调节ANGPTL4来抑制增殖,入侵,迁移和EMT,在CC中起到瘤抑制作用.
miR-627-5p作为宫癌的诊断生物标志物和治疗点具有显著的潜力.
进一步研究基于miRNA的疗法,可能利用纳米粒子传递系统,可以提高miR-627-5p在CC的精密医学中的有效性.

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...